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Microneedle arrays are an emerging technology that offers a novel drug delivery system to treat a
variety of skin wounds and diseases. The needles deliver therapeutics to the epidermis layer of
the skin and therefore establish advantageous qualities over the standard hypodermic needle as
they are non-invasive, efficient in biologic absorption, and can be self-administered. This project
investigates a custom 3D-printed hollow microneedle device created by a Santa Clara University
Senior Design team in 2018 for microencapsulated cell extrusion to be applied for accelerated
wound healing. The goal of our project is to operate in the therapeutic range for flowrate and
pressure to minimize patient pain and improve patient compliance. Simulations of laminar flow
and particle tracing through the 3D-printed microneedle device pre-puncture were generated
using COMSOL Multiphysics software. These results established a robust flow profile for fluid
flow and encapsulated cell tracing through the device when operating in optimal conditions. Next
various failure modes were analyzed to determine their effects on the flow profile. Tip
deformation, nozzle clogging, and suction were modelled using COMSOL, and respective
provisions were added to a failure modes and effects analysis (FMEA) matrix. In future
experiments, the generated flow patterns may be used as a machine learning data training set to
implement an algorithm that recognizes and predicts failure modes based on flow profiles.
Additionally, in situ flow data will be collected to compose a more robust model.
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Chapter 1 - Microneedle Arrays and Transdermal Drug Delivery
1.1 Introduction
The introduction chapter will provide the background information relevant to understanding our
design project and an overview of our project's objectives. Microneedle technology,
encapsulation of cells, and the VAS scale for pain metric formulation will establish the
background knowledge necessary to comprehend the importance of our design project.
1.1.1 Problem Statement
Microneedles offer painless therapeutic delivery and withdrawal of biological components
through the dermis layer of the skin. Our project addresses the demand of non-invasive medical
devices for drug delivery to minimize patient pain and induce improved patient compliance. By
operating within this therapeutic range, we will simulate laminar flow and microcapsule
trajectory through our 3D printed microneedle device in the pre-puncture stage. Using the
validated model, we will examine several failure modes in which the microneedles could
undergo due to 3D printing and determine their effect on flow profiles.
1.1.2 Project Proposal
Our project will be a continuation of previous years, which worked to capture the benefits of
cell-hydrogel therapies delivered by 3D printed micro-needles. This system is minimally
invasive, optimally painless, and offers treatment directly to the affected area. Our goal is to
minimize patient pain by optimizing the flow rate of suspended cells through the microneedles.
We also aim to test the reliability of continuous extrusion through all thirteen microneedles to
verify the treatment’s effectiveness.
Our project will contain two main goals for the 3D printed microneedles. For our first goal, we
will be to model laminar flow and particle trajectory in fluid flow through the microneedles
using COMSOL. We will model flow through a single needle in 2D and in 3D, as well as the
flow through the entire device in 2D and 3D. If allowed access into the lab, we would be
verifying the pressure of the flow for pain minimization using pressure sensitive tape. Once we
have validated our device using therapeutic ranges for flow rate and microcapsule extrusion, we
will model several failure modes that our device has the potential to undergo due to 3D printing
errors, microencapsulated cell errors, and human errors. To investigate the pain levels
experienced by patients, the pressure will be analyzed using pressure sensitive film if allowed
into the lab. Pressure sensitive film will simulate skin, where color change intensity indicates the
pressure experienced. This method will require some image analysis in order to collect data on
the quantity of pressure the pressure tape experiences.
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The target customers of the 3D printed microneedles are medical professionals in need of a
non-invasive technique for drug delivery systems for therapeutics. The use of 3D printed
microneedles is important as it is minimally invasive and reduces pain and anxiety in patients
undergoing treatment.
1.1.3 Project Justification
The previous group that worked on this project determined microencapsulated cells can
successfully be extruded from the microneedle device while maintaining viability. However, in
the absence of laboratory access and the ability to quantify shear, the most logical step is flow
visualization and in silico creation of failure modes. When conducted under therapeutic flow
rates, flow visualization and particle tracing will generate predictive profiles of biologic delivery
pre-puncture.
1.1.4 Medical Importance
Drug delivery methods that provide innovative techniques of administration are important in the
medical field as individualized medicine is becoming a focus for treating patients with unique
diseases. Transdermal drug delivery is a pressing field for drug delivery systems as this method
is noninvasive and can be self-administered by patients. It is estimated that 20% of the adult
population suffers from needle phobia and are more likely to avoid receiving the medical care
they need [13]. By proposing a method of drug delivery that can minimize pain and be
self-administered, patients will have an increased compliance to receiving medical attention.
This is applicable in today's world as SARS-CoV-2 has been infecting and spreading to millions
of people and a vaccine delivered by a hypodermic needle is currently the best method to help
prevent spread of infection. The use of microneedles to deliver vaccines to people will
potentially increase the amount of people willing to receive a vaccine. Once this technology is
further developed, an entirely new, non-invasive, and reliable way of delivering cells to patients
with various diseases will be available to patients.
1.1.5 Virtual Plan
Due to COVID-19 restrictions, we were not able to go into the lab to print and test our 3D
microneedles and microencapsulated cell extrusion. Instead, we focused on validating the design
of the 3D printed microneedles using COMSOL Multiphysics software. COMSOL is a
cross-platform finite element analysis, solver, and multiphysics simulation. We utilized the
software to test our design using different physics simulations including laminar flow and
particle tracing in fluid flow. We also tested multiple failure modes of the 3D printed artifacts to
determine their effects on flow profiles. Using COMSOL allowed us to keep our project virtual
so we could all stay safe and help stop the spread of COVID-19.
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1.1.6 Project Objectives
Our aims for the project are the following:
1. Model one phase flow with particle tracing to simulate microcapsule trajectory through a
custom 3D printed device pre-puncture.
2. Validate model using COMSOL Multiphysics software to simulate multiple failure modes
of 3D printed artifacts.
1.2 Background
1.2.1 Microneedle technology
The expansion of the microelectronics industry began in the 1990s, with the first success in
developing a microneedle for the purpose of transdermal drug administration occurring in 1998
[5]. Transdermal drug delivery has various conditions it can be applied to, such as administering
medicine to combat tumors, diabetes, wound treatment, and scar repair. There are many types of
microneedles such as solid, coated, dissolving, hollow and porous microneedles. Transdermal
drug delivery is commonly achieved by utilizing one type of microneedle array called hollow
microneedle arrays which have been tested and developed for market production. Transdermal
drug delivery is advantageous over injection-mediated and oral administration due to increased
bioavailability, the fraction of the drug that enters the bloodstream and can contribute towards
healing. Furthermore, its ability to be self-administered presents a large improvement as it
increases the ease and accessibility of long-term drug administration over injection-mediated
drugs. One disadvantage is the impermeability of the skin, however with the correct geometry
and extrusion rates this can be overcome.
Figure 1. Various types of microneedles and how drugs are administered. [11]
The number of hollow microneedle publications increased drastically between 2008 and 2011
[2], during this time fabrication methods were being tested. Hollow microneedles are connected
to a reservoir which contains drugs that must be delivered to the patient. The reservoir is
advantageous because it allows larger quantities of drugs to be administered to the patient.
However, the disadvantages of this method include the complexity of fabrication processes and
specific application parameters which make it difficult to spread the use of this device
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throughout drug delivery in various medical treatments. This type of microneedle utilizes
diffusion or pressure-driven flow to dispense the drugs. The use of microneedles in drug delivery
is favorable to traditional methods of drug delivery such as syringe needles or oral drug delivery
due to:
● Ability to minimize pain through optimizing flow rates
● Ability to minimize pain through the dimensions of microneedles
● The direct absorption of drugs into blood circulation
1.2.2 Microencapsulation of particles
Microencapsulation was first patented in 1955 [16], this process protects cellular particles from
the external environment without affecting the medicinal properties of the cells.
Microencapsulation is most commonly used in pharmaceutical companies, as pills utilize this
technology, encapsulating particles that will interact with the body’s immune system once the
capsule deteriorates. This method of drug administration is effective as it allows particles to be
slowly released into the body.
Figure 2. Encapsulation of HepG2 cells within alginate microcapsules. (a) 3.5% (w/v) alginate capsules 2 h post-fabrication (Set
1, control); (b) 3.5% (w/v) alginate capsules at 24 h post-fabrication (Set 2, control); (c) 3.5% (w/v) alginate extruded capsules 2
h post-fabrication (Set 1); and, (d) 3.5% (w/v) alginate capsules extruded 24 h post-fabrication (Set 2). Scale bar indicates
100µm.Red arrows represent spheroid formation.[5]
Figure 2 demonstrates the encapsulation of HepG2 cells extruded through a microneedle device
performed by a Santa Clara Bioengineering team in 2018 [5]. Microencapsulated cell extrusion
using 3D printed microneedles is a new area of application for microneedles.
“Microencapsulation is a process by which individual particles of an active agent can be stored
within a shell, surrounded or coated with a continuous film of polymeric material to produce
particles in the micrometer to millimeter range, for protection and/or later release,” [8].
Microencapsulation effectively delivers active compounds to treat deficiencies or combat the
overgrowth of certain cells. It is imperative that microencapsulation:
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● Protects the encapsulated compound
● Increases the stability and length of the viability of the product
● Controls the release of the compound.
Microencapsulation prohibits cell extrusion at first and then allows cells to be dispersed
throughout the body. Cell extrusion is used in controlling cell counts and maintaining the
function of the barrier. Combining the microencapsulation of cells with microneedles presents
challenges as microneedles have been developed to deliver many types of drugs but not through
microencapsulation. The design of the microneedle must be reconsidered for this technology as
the shape and the speed of flow must limit the amount of shear stress on the extruded cells.
Additionally, developing this technology further would include the extension of adding sensors
to microneedle arrays, which will detect the condition of the patient and administer the
appropriate amount of medication. After considering the development of microneedles and
current innovations such as cheaper 3D printing methods and microencapsulated cell extrusion
using microneedles, the aforementioned improvements must be further experimented on.
1.2.3 Pain Minimization using Microneedles
A major advantage of microneedles when compared to hypodermic needles is they are relatively
painless. In “Effect of microneedle design on pain in human subjects” researchers found that
while thickness, width, and tip angle did not affect patient pain, length and number of
microneedles in the array did [9]. The study showed that the shortest tested length (480 um) and
smallest number (5) microneedles resulted in the lowest amount of pain experienced as
determined by visual analog pain scores. All pain scores indicated microneedles induced 5-40%
of the pain of a hypodermic injection. Pain is also often caused by breakages upon insertion,
which is usually found in glass and ceramic materials.
Relative to the range of lengths (480 -1450 um) and numbers of needles in arrays (5 - 50) tested,
our device would be predicted to land on the lower end of the pain scale, with a 13 microneedle
array, each 600 um long. So, according to available data on microneedle geometry’s influence on
pain, our microneedles are as close as printer resolution allows to painless delivery.
This study measured pain using the visual analog pain score, which is determined by drawing a
line along a ten centimeter scale, with zero indicating “no pain” and ten indicating “worst pain”.
Although this is a subjective, self assessment, it has been shown to be significantly better at
predicting pain than other subjective methods using digital scales.
Our device is for encapsulated cell extrusion, and infusion pressure will be monitored to
determine the optimal speed to minimize pain during injection. The study “Infusion pressure and
pain during microneedle injection into the skin of human subjects” found that flow rate does
influence pain experienced as measured by a VAS scale once reaching a certain threshold.
Similar geometry microneedles were tested at 0.1 mL/min, 0.3 mL/min, and 1 mL/min. When
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delivering the final amount of saline solution at 1 mL/min, patients reported “a sharp, piercing
sensation during the infusion of the last 0.2 mL, which suggests there was tissue damage,” [9].
Figure 3. VAS score as a function of needle depth and injected volume [10].
Because physiological markers of pain are more reliable, these should be monitored when
performing pain minimization studies.
Table 1. Physiological markers of pain used for potential parallel use in microneedle pain reduction studies.
Physiological Marker of Pain Summary
Heart rate variability (HRV)
The key to adequate pain management is assessing its
presence and severity, identifying those who require
intervention and appreciating treatment efficacy. The
experience of pain is complex, as reflected by its
definition as “an unpleasant sensory and emotional
experience, associated with actual or potential tissue
damage [3].
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Heart rate and blood pressure change
Cardiovascular Depth of Analgesia (CARDEAN) index has
shown a correlation with noxious stimuli in intraoperative
anesthesia [27].
Peripheral pulsatile component of cardiac cycle
Surgical plethysmographic index (SPI) guided drug
administration during intraoperative anesthesia “resulted in
reduced opioid consumption and faster recovery.” In
post-operative environments, moderate sensitivity and
specificity was found in distinguishing the difference between
low, moderate, and severe pain [27].
Electrodermal activity
Postoperative correlation between fluctuations of skin
conductance (NFSC) and pain scores in adults but not
children. In healthy test subjects there was correlation
between heat evoked pain and NFSC, however it is
unreliable due to large variability [27].
Pupil reflexes
Pupillary dilation reflex (PDR) is correlated to verbal ratin
postoperative procedures [27].
EMG response
P value between brain activity and PIPP score proved
positive correlation. The brain activity is stimulated
primarily by a change in behavioral components (such as
facial expression) rather than by a change in
physiological components [28].
1.2.4 Literature Review
Recent studies on microneedle technology investigate optimal fabrication methods, materials,
needle array parameters, needle geometries and morphologies. Goals of these studies include
high aspect ratio to increase tip sharpness, reduced production time, and maximized needle
strength. Each study proposes a specific set of characteristics for a microneedle array suiting a
unique purpose.
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Table 2. Studies of new applications and production methods for microneedle devices designed for transdermal drug
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450 μm height, larger
base area, and triple
needle were ideal
(withstood ~2.9 x
10^6 N/m2 of applied
stress).
Review articles summarize developments made in the field of microneedle in recent years, and
compare a wide range of microneedle types. Particularly emphasized are new fabrication
methods and materials.
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Chapter 2 - System Level
The current design of the microneedle device structure is composed of two main parts: one
containing the array of hollow microneedles, and the other consisting of a fluid chamber.
2.1 System Level Overview
Figure 4. SolidWorks representation of the device part containing an array of conical-shaped
microneedles with dimensions [5].
The bottom component of the device modeled in Figure 4 is a circular array of 15 conical-shaped
hollow microneedles, organized in a circular fashion. The dimensions of the cones are: 600μm in
height, a large opening diameter of 1,000μm, and a tip diameter of 400μm. The openings of the
hollow microneedles traverse through the part to the opposing surface, forming a hole for each
microneedle. The flat surface of this part will be glued to the larger circular surface of the fluid
chamber part. The fluid chamber is 15mm in height and 28.5mm in diameter. The opening where
the syringe will be loaded for injection has a diameter of 6.35mm and the larger circular surface
of the fluid chamber that will connect to the microneedle array is 11mm in diameter. This piece
serves as a fluid chamber to contain the liquid and cells dispensed by the syringe and is the




There are several methods of 3D printing microneedles, which use either direct or indirect
printing. These methods include stereolithography (SLA) and digital light processing (DLP),
where direct printing is the creation of microneedles to create the device, and indirect printing is
used to make a mould for the microneedles. Our design uses laser stereolithography (SLA) to
directly print hollow microneedles that protect microencapsulated cells from shear stress. Recent
literature explains that improvements within photopolymerization and extrusion-based 3D
printing depend on enhancing printing resolution and identifying the best material to confer the
desired material properties [22]. Our 3D printed microneedles are made out of Formlabs Clear
photoresin which is then printed using a Formlabs 2 printer. The liquid photoresin is a plastic
composed of short carbon chains that contains the necessary components of a final solid plastic
before polymerization. The SLA 3D printer uses UV light to cause the chains of the molecules to
link to form long and stiff carbon chains. When enough carbon chains link, they form a solid
plastic that makes up the 3D printed material of the microneedle device. The process of
polymerization of the carbon chains is demonstrated in figure 5.
Figure 5. Steps of Polymerization [6].
We were not granted access to the lab and were not able to utilize the SLA Formlabs Form 2
printer. Due to this protocol, we modeled our device on SolidWorks and focused on using
Multi-physics software to generate predictive profiles of biologic delivery pre-puncture.
2.3 Methods
This section will discuss the methods used to simulate laminar flow and particle trajectory
through the microneedle device. 2D and 3D interior geometries (Figure 6) were created in
COMSOL for analysis. This allows for modelling of the liquid extruded through the device
directly rather than as a liquid filling.
The COMSOL Simulations were performed using COMSOL Multiphysics Version 5.5.
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Figure 6. Center of microneedle device modeled as a solid for COMSOL simulations.
2.3.1 Laminar Flow Model
COMSOL was used to model laminar flow through the microneedle device to predict the flow
profile of solution upon extrusion. The Laminar Flow Interface on COMSOL is used primarily to
model flow at small to intermediate Reynolds numbers. The physics interface for single-phase
fluid flow is based on the Navier-Stokes equations.
Navier Stokes Equations
The Navier-Stokes equations govern the motion of fluids. These equations can be seen as
Newton's second law of motion for fluid flow. For a incompressible Newtonian fluid, the
equations are the following:
[1]ρ(𝑢 * ∇)𝑢 = ∇ * [− ρ𝑙 +  𝐾] + 𝐹 
[2]ρ∇ * 𝑢 =  0 
[3]𝐾 = µ (∇𝑢 +  ( ∇𝑢)𝑇)
where u is fluid velocity, p is fluid pressure, ρ is fluid density, and μ is fluid dynamic viscosity. F
is the volume force vector and K is zero because our flow is non-viscous and incompressible.
Equation 1 is a vector equation which represents conservation of momentum and Equation 2 is
the continuity equation that represents the conservation of mass.
Simulation Parameters
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Laminar flow was modelled through the device using the same dynamic viscosity and fluid
density as water: 8.90 Pa*s and 997 kg/m3 respectively. Inlet velocity was set to 1.58x10-4 m/s,
equivalent to that of 0.3 mL/min which falls in the therapeutic range for pain minimization.
2.3.2 Particle Trajectory Model
In order to visualize the flow of microencapsulated cells through the device, we ran a
time-dependent particle trajectory using the Particle Tracing Module on COMSOL. This module
is a general-purpose tool for computing the paths of particles as they travel through a geometry
and are subjected to various forces. The simulated particles in our study represent
microencapsulated cells that would be extruded through the device. Their trajectories are
computed in the time domain by solving a set of equations based on Newton’s Second Law of
Motion, to which the forces based on external fields can easily be added.
Drag Force
For laminar flow, the drag force contributes to the advective transport of the particles. The drag







(𝑢 −  𝑣)
The equation is based in Stokes Law, as the particles are small enough that the flow remains
laminar with a Reynold’s number below 2300, while Schiller-Naumann’s equation would be used
for turbulent flow with a higher Reynold’s number. represents the drag force, or friction force𝐹
𝑑
acting at the interface of the fluid and particles, while u and v are the velocities of the particle
and fluid respectively.
Simulation Parameters
The particles in our simulation have a diameter of 300 microns. The particle density is 1178
kg/m3, and the particle charge was set to zero. The boundary condition is the freeze boundary
which stops the particles when they hit a wall. The release condition is mesh based where the
particles are released from within each mesh element. This release condition best simulates a
syringe extruding the cells into the device.
24
Figure 7. Equations and Conditions for COMSOL Particle Trajectory
2.3.3 Failure Mode Analysis
Several failure modes were modeled including: clogged nozzle, deformed needle tip, and
suction. By creating potential defected geometries, velocity, pressure, and particle tracing plots
can be generated to determine the effect of the different failure modes. Then, by ranking the
negative effect of each failure mode, the processes will be addressed in order of descending risk
priority number. The risk priority number will be calculated using the equation below.
[5]𝑅𝑃𝑁 =  𝑆𝑒𝑣 * 𝑃𝑟𝑜𝑏 * 𝐷𝑒𝑡
2.4 Benchmarking Results
There have been various studies that have designed similar transdermal microneedle delivery
systems for drugs [10],[21]. However, there is only one study that has developed hollow
microneedles as a delivery system for cell therapy [7]. The study extruded non-cultured
epidermal cells (NCECs) through silicon hollow microneedles and observed positive NCECs
viability results; in addition, some of the injected NCECs maintained their function in  ex vivo
 human skin [7].
This study deviated from our project as they fabricated their microneedles using
photolithography [10],[21]. No other study has attempted to use 3D printing as their microneedle
structure fabrication method making this project a novel development.
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2.5 Key System Level Issues
The primary issue in our system is the reliability of software and simulations. There will
potentially be a discrepancy between our calculated results and simulated results. The
significance of this discrepancy needs to be experimentally determined with respect to the shear
on the microcapsules for optimized validation.
2.6 Bernoulli’s Equation and Continuity Equation
The following equation relates the flow rate (Q), in m3 per second to velocity (v), in m per
second and area (A), in m2. The initial flow rates were 0.3, 1.2 and 12 mL/minute, which were
converted to m3 per second. After using the equation the initial velocities were found and used in
the continuity equation.
[6]𝑄 = 𝑣 * 𝐴       
The continuity equation relates the change in velocity to the change in area as the mass is
conserved (shown below). This is necessary as the diameter of the device changes through the
initial chamber, the larger reservoir chamber,  the input of the microneedle, and the output of the
microneedle.
[7]𝑣1 * 𝐴1 = 𝑣2 * 𝐴2 
The following figure shows the geometry of the microneedle device, with the various diameters
used in calculations.
Figure 8. Velocity samples collected at four different locations for 0.3, 1.2, and 12 mL/min flow rates.
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Bernoulli’s equation relates the change in pressure to the change in velocity found from the
continuity equation. The following equation was used, with initial pressure set to the value used
in COMSOL, density ( ) set to the density of water, height (Z) changed based on the deviceρ
geometry, and area and velocity used from the previous equation.




ρ1 + 𝑔 * 𝑍2 +
𝐴1*𝑣2 2
2
2.7 Team and Management
Our team is composed of three student members and our advisor. We maintained weekly
communication since the founding of our group and project. Our project is a continuation of a
project created in 2018 under the supervision of our current advisor. We utilized a Google Drive
folder to collect our research and collaborate on simulations, MATLAB code, and literature
reviews. Weekly meetings were set up with our advisor to ensure productive progression of the
project. All members were trained and proficient in Solidworks, COMSOL, and MATLAB.
2.8 Risks
Due to our project being entirely virtual, we have no health or material risks. The main risk we
have in our design project approach is having discrepancies in reality versus simulations. Our
simulations will generate predictive models of the flow profile of the device, however the
significance of these potential discrepancies needs to be experimentally determined.
2.9 Timeline
Fall 2020 Winter 2021 Spring 2021
❏ Outline goals for project
❏ Budget and funding
❏ Literature review
❏ COMSOL Simulations of
fluid mechanics and flow
rate
❏ 3D print microneedles using
Maker Lab
❏ Verify that previous
results can be replicated
❏ Test reliability of needles
using flow modeling
❏ Perform pressure analysis to
minimize pain
❏ Create a larger-scale model
❏ Model/monitor cell extrusion
efficacy
❏ Finish results analysis
❏ Write thesis report
❏ Publish our findings





COMSOL Software Package NA School Of Engineering
MatLab Software Package NA School Of Engineering
3D Printing Materials and Labor SCU Maker's Lab $200.00
Scanning Electron Microscopy/ Atomic
Force Microscopy SCU CNS $600.00
Pressure sensitive paper $299.00
NIST Particles $365.00
Blue Dextran dye Sigma Aldrich Department of Bioengineering
Biopolymers N/A Department of Bioengineering
Disposables (1 mL syringes) Thermo Fisher Department of Bioengineering
syringe pump New Era Department of Bioengineering
Camera Biomomentum Department of Bioengineering
Sterilization NA Department of Bioengineering
Cell culture NA Department of Bioengineering
$1,464.00
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Chapter 3 - Subsystems Level
Figure 9. Subsystems flowchart.
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Chapter 4 - Simulation Results and Discussion
The purpose of this chapter is to present the results for the studies that we performed in
COMSOL. These simulations developed a flow profile for the custom microneedle device. We
tested a single-phase stationary laminar flow and time-dependent particle tracing through fluid
flow through our validated model. We also tested three different failure models using our device
to evaluate their effect on the flow profiles. The three failure models are a clogged nozzle, a
disformed nozzle, and suction.
4.1 Flow Profiles
4.1.1 Study 1: Stationary Laminar Flow
As stated previously, the conditions of the laminar flow are as follows:
Dynamic Viscosity:  8.90 × 10−4 Pa·s
Density: 997 kg/m³
Inlet Velocity: 1.58x10−4 m/s
(a) (b)
Figure 10. COMSOL results graphs. (a) Slice plot of velocity magnitude for laminar flow (m/s). b) Contour pressure
plot for laminar flow (Pa).
The outlet velocity through the 13 nozzles is about 5.3x10−3 m/s. The pressure through the 13
nozzles is about 0.08 pascals. This outlet velocity is optimal for pain minimization based on
Gupta et. al.’s study on flow rate as discussed in Chapter 1.1.  To verify the force of the flowrate
pre-puncture, we modeled the impact force through the nozzles using the impact force equation.
The impact force through the nozzles is about 2.1x10−10 newtons.
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[9]𝐼𝐹 =  ρ𝑣²𝐴 
(a) (b)
Figure 11. (a) Cut-line across device to calculate impact force is located across five nozzles at the beginning of the
needle. (b) Graph of impact force across five needle in Newtons
4.1.2 Study 2: Time-Dependent Particle Trajectory
As stated previously, the conditions of the particle trajectory are as follows:
Particle diameter (dp): 300 μm
Particle density (⍴): 1178 kg/m3
Charge number: 0
Figure 12. Particle Tracing plot at 2 seconds
The particle trajectory image is captured at 2 seconds post particle injection. The image
demonstrates the particles flowing through the device and traveling down the needles’ chambers.
The particles seen stationary at the top of the device are a result of the wall freeze condition set
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by COMSOL. The color scale on the right of Figure 12 represents the particles’ velocities in
meters per second; the fastest particles are congregated in the needle tip, and the slowest particles
are either cemented to the boundary or halted at the base of the device. The flow of particles
enters the center nozzles at a faster rate than the outer nozzles as a result of the cone-like
geometry. This is to slow the velocities of the particles through the device to maintain a
therapeutic flow rate for pain minimization.
4.2 Failure Models
4.2.1 Clogged Nozzle
The first failure mode we investigated is a clogged nozzle. This failure may occur due to
microcapsule aggregation that is strong enough to halt particle and fluid flow through the needle
tip. Clogging may also occur due to a printing defect such as nozzle shrinking below the
designed 400 micron diameter. This type of 3D printing defect may occur as a result of deficient
polymerization. When the printer inadequately polymerizes the resin from a liquid to a solid, the
structural integrity of the microneedle tip is compromised. Finally, the encapsulation of the
mammalian cells may not be uniform, resulting in microencapsulated cells with a diameter
greater than 300 micron. As a result of uneven size distribution, the microencapsulated cells may
be too large to pass through the needle, resulting in a clogged nozzle.
In COMSOL, we modeled a clogged needle by deselecting either one nozzle, or several nozzles
as an output option in the laminar flow module. Figure 13 shows the results of the center
theoretically clogged.
(a) (b) (c)
Figure 13. Velocity, pressure, and particle trajectory plots demonstrating the center nozzle as clogged
By clogging the center nozzle, the remaining nozzles who still experienced flow have an
increased outlet velocity of 5.5x10−3m/s and a pressure increase from 0.08pa to 0.09pa. As there
was no laminar flow through the center nozzle, no particles traveled through the needle chamber.
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This is a discrepancy from what one may expect in the lab as the particles may have been the
cause for the clogged nozzle and would therefore appear in a particle trajectory plot.
(a) (b)
Figure 14 . (a) One dimensional graph of Impact force plot of 5 needles with center needle clogged. (b) Plane plot
of impact force of all 15 needles with center needle clogged.
The impact force through the clogged nozzle is zero which has logical integrity as there is no
flow traveling through the needle tip, and therefore no velocity at the point of measurement. The
impact force of the surrounding nozzles increased to about 15x10−10 N as they experienced a
higher velocity as a result of the clogged nozzle.
To prevent the occurrence of this failure mode, clogged nozzle provisions should be in place.
Before encapsulation of the cells, one should explore the use of surface coating to reduce the
chance of particle aggregation. This may be done by giving the particles a charge to reduce their
probability of sticking together. During testing, one should implement a design method to
visually inspect the microneedles under a microscope to capture clogging. After testing, one may
also reoptimize the parameters for the atomization processes and reinforce microscope inspection
prior to infusion of microcapsules into the device.
4.2.2 Deformed Nozzle
The second failure mode we investigated is a deformed needle tip. This particular failure mode
could occur in the lab due to denting of the tip as a result of a shortened washing step post 3D
printing. The washing step is critical to remove all non crosslinked polymers present in the
device. If this step is not performed properly, then the 3D printed microneedles have the risk of
being disformed. The material that makes up the device is brittle in nature and is at high risk of
experiencing a random fracture that could disrupt the uniformity of the device. Deformation may
also occur due to a CAD defect if the device is not modeled properly.
One way in which the deformed nozzle was modeled in COMSOL is by shrinking the needle tip
from 400 microns to 200 microns which is most likely to occur due to a CAD defect.
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(a) (b) (c)
Figure 15. Velocity, pressure, and particle trajectory plots demonstrating a disformed center needle from 400
microns to 200 microns in diameter.
When the center needle was shrunk to 200 micron, its velocity experienced a decrease from
5.3x10−3 m/s to 4.0x10−3 m/s. The nozzles that did not undergo deformation had an increased
velocity of 5.5x10−3m/s. The pressure of the deformed nozzle increases to 0.20 Pa and the
un-changed nozzles slightly increase to 0.09 Pa in comparison to the control experiment which
has a pressure of 0.08 Pa. Particles still traveled to the deformed nozzle, however, congregated at
the base of the nozzle as they are too large to pass through.
(a) (b)
Figure 16. (a) One dimensional graph of impact force plot of 5 needles with center nozzle deformed. (b) Plane plot
of impact force of all 15 needles with center nozzle deformed.
The impact force of the unchanged nozzles increased from 2.1x10−10N to 14.5x10−10N while the
deformed nozzle’s impact force was 3x10−11N. The center nozzle has a decreased impact force
because the velocity is lower in the deformed tip as it has a smaller cross sectional area for the
flow to travel through. Since less fluid can travel through the deformed tip, the remaining
needles will experience a higher velocity of fluid flow and therefore have a greater impact force.
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To prevent the occurrence of this failure mode, deformed  nozzle provisions should be in place.
One provision is to increase the wash time after cross-linking the device’s photo resin to
guarantee a smooth transition from liquid resin to solid resin. Another provision is to design a
visual inspection under the microscope to investigate a deforemd nozzle as well as design a
Charpy test for the microneedles. Finally, the handler should always revise the CAD design
before submitting the device plans to the 3D printer.
4.2.3 Suction
Suction is used to sample microcapsules for quality as a routine test prior to therapeutic use. If
the vacuum palette is uneven, the force will be applied heavily to a single nozzle. The additional
shearing of the capsules may cause cellular damage and result in an inaccurate sample of
extruded microcapsules, rendering the suction test non functional.
Suction was modeled in COMSOL by setting the pressure of the nozzle experiencing suction to
-500 Pa while keeping the remaining nozzles at 0 Pa. Figure 17 denotes the center nozzle
experiencing suction.
(a) (b) (c)
Figure 17. Velocity, pressure, and particle trajectory plots demonstrating suction on the center needle with an outlet
pressure of -500 Pa.
The center nozzle undergoing a pressure of -500 Pa, experienced a velocity of 0.7m/s. This is
almost three times the magnitude of the control laminar flow experiments and is due to the
significant pressure difference experienced by this nozzle compared to previous experiments.
The remaining nozzles experience a velocity of 0.05 m/s. The pressure of the center nozzle post
laminar flow is -300 Pa while the remaining nozzles have a pressure of 0 Pa. As a result of this
uneven pressure distribution, the only particles that were traced for the particle trajectory plot are
at the nozzle tip of the center nozzle, at the base of the center nozzle, and at the top of the device.
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(a) (b)
Figure 18. (a) One dimensional graph of Impact force plot of 5 needles with center nozzle experiencing suction. (b)
Plane plot of impact force of all 15 needles with center nozzle experiencing suction.
The impact force of the center nozzle is 3.2 x10−5N while the remaining nozzles are about
2x10−7N. Pressure does not directly affect impact force, however, the center nozzle is
experiencing a greater impact force than the other nozzles due to ite higher velocity inside the
nozzle. In the case where suction was not applied (control), the value of the impact force was
2x10−10N. The values differ by 3 orders of magnitude suggesting that suction does affect the
neighboring nozzles. However, the significance of this discrepancy needs to be experimentally
determined with respect to the shear force on the microencapsulated cells.
Designing a vacuum palette to sample from the nozzles evenly will allow the suction to be
incorporated into our workflow as a provision for routine microcapsule integrity and cell quality
monitoring.
4.3 Flow Verification
In order to ensure that COMSOL derived values for impact force and output nozzle pressure
were plausible, Matlab was used to calculate expected velocities derived from the Bernoulli’s
and Continuity equations.
4.3.1 Laminar Flow
The first step in validating the model is checking that the observed flow is laminar. Bernoulli’s
equation and the continuity equation, which will be later used to evaluate our theoretical model,
rely on laminar flow conditions. In cylindrical ducts, such as microneedle shafts and the
connected reservoir, Reynold’s number should be below 2300 to qualify as laminar flow. Table 4
below shows the mean Reynold’s number calculated for each of the tested flowtates, all well
below the threshold.
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Table 4. Calculations of the mean Reynold’s number at each flowrate to ensure that flow is laminar.




Laminar flow varies throughout the device and peaks at areas of stagnation, which were detected
by plotting Reynold’s number vertically down the center of the device, as illustrated in Figure X.
Stagnation peaks at 4.73 mm and 15 mm, the two areas where the device suddenly narrows.
(a) (b)
Figure 19. (a) Reynold’s number plotted as a function of height in millimeters through the center of the device. (b)
The stagnation zone detected in Plot A at height 4.73 mm.
Figure 20. Velocity profiles across horizontal cutlines at locations V1-V4 as specified in Figure 8.
37
These flow profiles demonstrate how velocity varies across the diameter of the cylinder at each
of our four locations. The V1 profile is based on the uniform input flow rate, therefore the
velocity profile is relatively uniform across the diameter. The other three velocity profiles show
the fastest velocity is at the center of the cylinder at each location.
● Location 1: The flow is not fully developed. Entrance effects need to be taken into
consideration by the theoretical model.
● Location 2: The flow is displaying an entrance region profile.  In addition, there is the
discrepancy as a function of a cumulative error from location 1.
● Location 3: The flow is past a stagnation zone and is not fully developed, displaying an
entrance region profile. There also is also a cumulative error resulting from the steps
above.
● Location 4: The flow is fully developed. The discrepancy is a result of a cumulative error.
4.3.2 Theoretical vs. Simulated Fluid Velocity
Velocity was sampled at four locations within our COMSOL model; V1 is the entrance velocity,
V2 is the velocity as the reservoir narrows, V3 is the velocity as the fluid enters the microneedle
shaft, and V4 is the final velocity as the fluid is extruded. These locations were selected because
they represent the four different zones of the device, each with a unique diameter. The
corresponding theoretical velocity values were generated using the continuity equation. They
were calculated at all three of our tested flow rates. The theoretical values for the flow rate of 0.3
mL/min are compared with their corresponding COMSOL sample values in the table 5. The
velocities have the same order of magnitude, but the discrepancy between the values increases
from top to bottom.
Table 5. Comparison of theoretical and COMSOL derived velocities at each location specified in Figure X for an
initial flow rate of 0.3 mL/min.
Location Theoretical Velocity (m/s) COMSOL Velocity (m/s)
V1 1.5788 x 10-4 1.5922 x 10-4
V2 3.9789 x 10-4 3.5972 x 10-4
V3 4.8971 x 10-4 2.8546 x 10-4
V4 3.0607  x 10-3 5.3467  x 10-3
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Table 6. Comparison of theoretical and COMSOL derived velocities at each location specified in Figure X for an
initial flow rate of 1.2  mL/min.
Location Theoretical Velocity (m/s) COMSOL Velocity (m/s)
V1 6.3158 x 10-4 6.4875 x 10-4
V2 1.5915 x 10-3 1.4183 x 10-3
V3 1.9588 x 10-3 1.1193 x 10-3
V4 1.2243 x 10-2 2.1681  x 10-3
Table 7. Comparison of theoretical and COMSOL derived velocities at each location specified in Figure X for an
initial flow rate of 12 mL/min.
Location Theoretical Velocity (m/s) COMSOL Velocity (m/s)
V1 6.3153 x 10-3 6.3783 x 10-3
V2 1.5915 x 10-2 1.3686 x 10-2
V3 1.9588 x 10-2 1.1566 x 10-2
V4 1.2243  x 10-1 2.1370  x 10-2
When examining why discrepancies accumulate as fluid moves downward through the device, a
modified version of Bernoulli’s equation was created which takes into account the work done by
the syringe pump required to move fluid into the reservoir, and the heat lost due to friction as the








2  +  𝑊𝑝𝑢𝑚𝑝 =
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2  +  ℎ𝑓𝑟𝑖𝑐𝑡𝑖𝑜𝑛  
p1:  Input pressure (Pascals)
⍴:  Density of the fluid (kg/m3)
g:  Acceleration due to gravity (m/s2)
z1: Upper height (meters)
Wpump: Work to pump fluid through device (kg*m2/s2)
p2: Output pressure (Pascals)
z2: Lower height (meters)
hfriction: Loss due to friction in needle tip (kg*m2/s2)
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Although possible that the work and friction terms could have cancelled out, this was not the
case and thus errors accumulated within the device.
Table 8. Calculations of each term in Equation 9 in order to identify the sources of discrepancy between our
theoretical and experimental velocity values.
TOP (Device) BOTTOM (Nozzle)
p/rho 0.00002781 p/rho 0
v2/2 1.2482E-08 v2/2 0.000000245
gz1 0.19943 hfriction 0.026579592
Wdevice(J/s) 0.172877986
mass flowrate (kg/s) 0.000005
Wdevice(W) 9.00E-07
TOP (Nozzle) BOTTOM(Nozzle)
p/rho 0.0000128 p/rho 0.000009
v2/2 2.4642E-08 v^2/2 0.000000125
gz1 0.00588 hfriction 0.000783673
Wdevice(J/s) 0.0058837
mass flow rate (kg/s) 0.000001
Wdevice(W)/nozzle 6.00E-09
4.4 Failure Modes and Effects on Analysis
The failure modes and effects analysis (FMEA) matrix is used to identify various possible modes
of failure in a design. The overall risk of failure is calculated using three components: the
severity, probability, and detectability of failure. Each of these components is rated on a scale of
one to ten, with one being the most ideal, and ten being the least ideal. The risk priority number
(RPN) is calculated by multiplying these three values, which is shown in the table above. The
table has been split into three sections, first, the process FMEA encompasses possible failures in
design, manufacturing, and assembly before the device is distributed to the intended users.
Secondly, the user FMEA which encompasses possible failures attributed to the user improper
use of the device. Lastly, the COMSOL-based FMEA which encompasses the failure modes
modeled in COMSOL that could be simulated due to improper geometry and particle-related
errors. The matrix is ordered in descending order, from highest RPN to lowest RPN as the item
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with the highest number requires the most attention. In the FMEA, the current design control is
listed to explain how the developers are reducing the probability value, however, modes of
failure that did not have a current design control were given one in the “recommended actions”
column. By creating the FMEA we created a crucial component to identify and improve
reliability issues of the device. The corresponding tables are shown below.
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pre-submission to 3D printer.
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Chapter 5 - Engineering Standards and Constraints
5.1 Manufacturing
The design project meets the engineering standard of being manufacturable due to its production
methods. Our design would be fabricated through 3D printing using standard 3D printer
materials including photo resin. Due to Covid-19, we were not able to enter the lab and our
design project used no materials and therefore did not require manufacturing
5.2 Sustainability
The design project meets the engineering standard of being sustainable because we did not use
any materials or biological materials in our project. The device that we are simulating is
sustainable when physically manufactured because it proposed a reusable platform. The robust
design includes only the syringe to be refillable with matrix between each use making the device
more sustainable than a single use hypodermic needle.
5.3 Health and Safety
The design project meets health and safety requirements because no cells were handled and the
device was not used to penetrate the skin. For future management of the physical device,
cytotoxicity tests need to be performed to ensure the safety of the needle penetrating skin and
interacting with the encapsulated cells.
5.4 Social
Additionally, the design project meets social standards because it addresses the problem of
minimally invasive drug delivery methods to reduce needle phobia. Microneedles only enter the
epidermis layer of the skin and are therefore virtually pain free. People who have a fear of
hypodermic needles will be more comfortable and feel safer receiving the care they need through
the use of microneedles.
6.5 Economic
Lastly, the design project meets economic standards because we did not order any materials and
executed our entire project on COMSOL Multiphysics software. The base COMSOL license cost
is $4000, however we had access to a free license through Santa Clara University.
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Chapter 6 - Summary and Conclusion
6.1 Summary
The main objective of our project was to model a one phase laminar flow and time-dependent
particle trajectory through our custom microneedle device on COMSOL Multiphysics
pre-puncture within the therapeutic flow rate for pain minimization. We also aimed to model
multiple failure modes of 3D printed artifacts to build a more robust flow profile of our
microneedle device. These objectives will lead to an optimized microneedle device that is a
minimally invasive system capable of extruding cells transdermally for cell therapy purposes.
The COMSOL laminar flow interface utilizes the Navier Stokes equations which govern the
motion of fluids. These equations can be seen as Newton's second law of motion for fluid flow.
We ran a single-phase, stationary laminar flow on our device using the following constraints: an
inlet velocity of 1.58x10−4m/s, an inlet pressure of 0 Pa, a dynamic fluid viscosity of 8.90 × 10−4
Pa·s and, a fluid density of 997 kg/m³. The average outlet velocity of the microneedles was
2.82x10−3m/s or 0.45 mL/min which falls slightly above the therapeutic flow rate range for pain
minimization based on the VAS scale. We were able to successfully optimize the flow rate for
pain minimization so future handlers of our device will have injection conditions that augment
non-invasiveness.
In order to visualize the flow of microencapsulated cells through the device, we ran a
time-dependent particle trajectory using the Particle Tracing Module on COMSOL. This module
is a general-purpose tool for computing the paths of particles as they travel through a geometry
and are subjected to various forces. The particle trajectory constraints we implemented are: a
particle diameter of 300μm, a particle density of 1178 kg/m3, and a particle charge number of 0.
After running the particle trajectory simulation on the device, the fastest particles traced are
congregated in the needle tip, and the slowest particles are either cemented to the boundary due
to the boundary freeze condition in COMSOL or halted at the base of the device. The flow of
particles enters the center nozzles at a faster rate than the outer nozzles as a result of the
cone-like geometry of the interior of the flow chamber. This geometry was implemented to slow
the velocities of the particles through the device to maintain a therapeutic flow rate for pain
minimization.
We examined several failure modes that the microneedles could undergo due to a handler error
or 3D printing and determined their effect on flow profiles. The first failure mode we
investigated was a clogged nozzle. This could occur due to particle aggregation, printing defects
as a result of inadequate polymerization, or uneven microcapsule size distribution. When a
needle is clogged, the velocity, pressure and impact force of the surrounding nozzles increase.
No particles interact with the clogged nozzle because the clogged nozzle does not experience
fluid flow. Provisions that may be executed to help reduce the probability of this failure are:
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explore the charge of the biocompatible polymer encapsulating the cells, design a visual
inspection of the procedure under a microscope, reoptimize parameters for atomization processes
and reinforce additional microscope inspections prior to infusion of cells into the device. The
next failure mode we investigated is a deformed nozzle. Deformation may be caused by denting
due to a short washing process post fabrication, chipping as the material is brittle and easily
fractured, or a CAD defect. When the nozzles are deformed in the way that shrinks the nozzle
tip, the velocity through the deformed nozzles decreases and the velocity through the
non-deformed nozzles increases. The pressure of the deformed nozzles increases and the
surrounding nozzle pressures increase very slightly. Particles tended to aggregate in the
deformed nozzle but were too large to pass through the needle tip. Provisions that may be
executed to help reduce the probability of failure are: increase the wash cycle time after the
photoresin has cross-linked, design a visual inspection under the microscope, design a Charpy
test for the microneedle array, and revise the CAD submission prior to 3D printing. The last
failure mode we simulated is suction. Suction is used to sample microcapsules for quality as a
routine test prior to injection for therapeutic purposes. If the vacuum palette is uneven, the force
will be applied heavily to a single nozzle. The additional shearing of the capsules causes cellular
damage and the damaged cells will not be an accurate sample of extruded microcapsules,
rendering the suction test non functional. When suction is applied to a single nozzle of our
microneedle system, only that nozzle will experience velocity, pressure, and interact with
particles. The velocity and pressure experienced by the failed nozzle is significantly larger than
the velocity of the control experiment due to the extreme pressure difference. A provision that
may be executed to help reduce the probability of failure is to design a vacuum palette that can
evenly sample the nozzles so that the vacuum force does not apply an increased force to a
particular nozzle.
6.2 Conclusion
In conclusion, we were successfully able to model a one phase laminar flow and a
time-dependent particle trajectory through our custom microneedle device on COMSOL
Multiphysics pre-puncture within the therapeutic flow rate for pain minimization. We also
successfully modeled multiple failure modes of 3D printed artifacts to build a more robust flow
profile of our microneedle device. Our device is a non-invasive and targeted method for cell
delivery into the epidermis layer of the skin for therapeutic usage.
6.3 Future Work
In upcoming experimental studies, deviations from expected flow patterns will enable the
measurement of shear experienced by microencapsulated cells, and their subsequent viability.
Building new automated soft sensors enabled by the simulated library of flow defects in
conjunction with cell viability studies will generate training sets for validation studies through
machine learning.
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Fujifilm Prescale pressure sensitive paper in the Ulta Extreme Low pressure range (0.87-7.3 PSI)
was sourced from Sensor Products Inc. The paper reacts to pressure by breaking microcapsules
when force is applied creating an image indicating where the greatest color change is relative to
the highest impact force. This result can be analyzed by Sensor Product Inc. to provide
quantitative results in PSI. In future works pressure sensitive paper would serve to
experimentally validate the exit pressure predicted by the laminar flow model.
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Chapter 8 - Appendix
8.1 Other Deformed Nozzle Simulations
8.1.1 Increased Tip Diameter
To simulate an increased tip diameter, which may have been caused by a breakage, we increased
the diameter of the center nozzle from 400 micrometers to 600 micrometers. Figure X
demonstrates the results from the laminar flow and particle trajectory.
Figure 21. Velocity, pressure, and particle trajectory plots demonstrating suction on the center needle with an
increased diameter of 600 microns.
The outlet velocity of the center nozzle that has a tip diameter of 600 micrometers is 3.7x10-3 m/s
while the remaining nozzles had a velocity of 5.1x10-3 m/s. If the needle tip has a larger diameter,
then it will experience a slower velocity extruding through the nozzle. The pressure of the center
nozzle was about 0.04 Pa while the remaining nozzles had an increased pressure of 0.14 Pa.
More particles were able to travel to the tip of the center nozzle due to its larger diameter.
Particle trajectory did not show any significant discrepancies with a larger tip diameter.
The impact force graphs show that the center nozzle had a higher impact force than the
remaining nozzles due to its larger surface area. The impact force of the center nozzle is
2.8x10-6N while the unchanged needles have an impact force of 1.0x10-6 N.
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Figure 22. (a) One dimensional graph of impact force plot of 5 needles with center nozzle at a 600 micron diameter.
(b) Plane plot of impact force of all 15 needles with center nozzle at a 600 micron diameter.
8.1.2 Slated Tip
To simulate a slanted nozzle tip, we modeled the geometry in 2D to create a more accurate model
for our failure mode. We simulated a slanted tip by making the right corner of the tip 200
micrometers above the left corner of the tip in 2D. Based on this geometry, the new diameter of
the tip is 447.2 micrometers.
Figure 23. 2D velocity, pressure, and particle trajectory plots demonstrating a slanted center
nozzle.
The outlet velocity of the slanted needle is 3.7x10-4 m/s while the remaining nozzles have an
outlet velocity of 3.5x10-4 m/s. The particle trajectory plot experienced no significant
discrepancies.
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